PRESS RELEASE published on 11/25/2025 at 18:33, 2 months 14 days ago Inside Information / Other news releases ABIONYX Pharma reports €3.06 million revenue and €2.8 million cash position as of Q3 2025. Expands focus on sepsis and rare diseases Revenue Cash Position ABIONYX Pharma Sepsis Q3 2025
PRESS RELEASE published on 11/25/2025 at 18:33, 2 months 14 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma communique sur son activité et sa trésorerie du 3ème trimestre 2025. Chiffre d’affaires consolidé de 3,06 M€ et trésorerie de 2,8 M€ au 30 septembre 2025 Chiffre D’affaires Biopharmaceutique Trésorerie ABIONYX Pharma Trimestre 2025
BRIEF published on 11/12/2025 at 07:05, 2 months 28 days ago ABIONYX Pharma en discussions avancées avec l'IHU SEPSIS Partenariat Stratégique ABIONYX Pharma Sepsis IHU SEPSIS Biomédicaments
BRIEF published on 11/12/2025 at 07:05, 2 months 28 days ago ABIONYX Pharma is in advanced discussions with the IHU SEPSIS Strategic Partnership Biopharmaceuticals ABIONYX Pharma Sepsis IHU SEPSIS
PRESS RELEASE published on 11/12/2025 at 07:00, 2 months 28 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce des discussions stratégiques avancées avec l’IHU SEPSIS, 1er centre mondial dédié au sepsis, pour une alliance structurante et transformante dans le traitement global du sepsis Alliance ABIONYX Pharma Sepsis Discussions Stratégiques IHU SEPSIS
BRIEF published on 10/21/2025 at 18:54, 3 months 19 days ago Validation génétique de l'ApoA-I dans le sepsis par ABIONYX Pharma ABIONYX Pharma Thérapies Innovantes Apolipoprotéine A-I Septicémie Validation Génétique
BRIEF published on 10/21/2025 at 18:54, 3 months 19 days ago Genetic validation of ApoA-I in sepsis by ABIONYX Pharma Innovative Therapies ABIONYX Pharma Sepsis Apolipoprotein AI Genetic Validation
PRESS RELEASE published on 10/21/2025 at 18:49, 3 months 19 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma annonce une validation historique dans la revue NATURE confirmant la causalité génétique de l'apolipoprotéine A-I (ApoA-I) dans le sepsis. Une avancée majeure dans le traitement de la septicémie Validation Historique ABIONYX Pharma Nature Septicémie Causalité Génétique
PRESS RELEASE published on 10/21/2025 at 18:49, 3 months 19 days ago Inside Information / Other news releases ABIONYX Pharma announces groundbreaking genetic validation study published in NATURE confirming Apolipoprotein A-I (ApoA-I) causality in Sepsis, reshaping critical care medicine ABIONYX Pharma Sepsis Genetic Validation Study NATURE Publication Apolipoprotein A-I
BRIEF published on 10/06/2025 at 15:00, 4 months 3 days ago Threshold crossing by the Caisse des dépôts et consignations in ABIONYX PHARMA Voting Rights CDC Threshold Crossing Bpifrance ABIONYX
Published on 02/10/2026 at 08:00, 31 minutes ago Caledonia Mining Corporation Plc - Issue of Securities Pursuant to Long Term Incentive Plan Awards
Published on 02/10/2026 at 01:05, 7 hours 26 minutes ago Notification of Relevant Change to Significant Shareholder
Published on 02/09/2026 at 23:35, 8 hours 56 minutes ago Mako Mining Announces Intention to Restructure the Mt. Hamilton Acquisition Consideration and Postponement of Special Meeting of Shareholders to New Meeting Date of March 3, 2026
Published on 02/09/2026 at 23:15, 9 hours 16 minutes ago IBC Advanced Alloys to Present at the Precious Metals & Critical Minerals Virtual Investor Conference on February 10, 2026
Published on 02/09/2026 at 23:08, 9 hours 23 minutes ago NV Gold Announces Closing of Non-Brokered Private Placement
Published on 02/10/2026 at 07:00, 1 hour 31 minutes ago EQS-Adhoc: ams OSRAM post Q4 above mid-point of guidance, delivers EUR 144 m FCF in FY25 and launches EUR 200 m ‘Simplify’ transformation and savings program
Published on 02/10/2026 at 07:00, 1 hour 31 minutes ago Waga Energy: Croissance de +23 % des revenus de production de biométhane en 2025
Published on 02/10/2026 at 07:00, 1 hour 31 minutes ago TUI delivers best Q1 performance with Und. EBIT of €77m, growing strongly by +€26m. We reaffirm our FY26 guidance of +7-10% Und. EBIT growth (at CC), driven by expectations for Summer 2026
Published on 02/10/2026 at 07:00, 1 hour 31 minutes ago Waga Energy posts a +23% yoy RNG production revenue growth
Published on 02/09/2026 at 18:00, 14 hours 31 minutes ago LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 46 minutes ago Declaration of voting rights at the end of January 2026
Published on 02/09/2026 at 17:45, 14 hours 46 minutes ago DAMARTEX / Droits de vote bruts et réels au 31 janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 46 minutes ago Déclaration des droits de vote à fin janvier 2026
Published on 02/09/2026 at 17:45, 14 hours 46 minutes ago Déclaration des droits de vote à fin janvier 2026
